Burjeel Holdings Champions Climate-Resilient and Innovative Healthcare Solutions at World Economic Forum - Middle East Business News and Information
Dr. Shamsheer Vayalil joined esteemed global leaders to discuss critical healthcare challenges posed by climate change.
DAVOS: Burjeel Holdings, a leading super-specialty healthcare services provider in the MENA region, highlighted its groundbreaking initiatives that incorporate climate change considerations into healthcare delivery, while also driving scalable solutions in the fight against cancer, at the World Economic Forum.
During a high-level roundtable discussion titled 'Investing in Healthcare: A Prescription for Climate Resilience?', Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, joined distinguished global leaders to address critical healthcare challenges.
The discussion centered on overcoming key roadblocks and identifying transformative opportunities for developing and funding innovative health solutions tailored to a climate-impacted future. Participants explored how collaboration and targeted investment can drive a proactive, resilient approach to safeguarding global health amid the challenges posed by climate change.
Burjeel's Initiatives in Climate-Resilient Healthcare:
Dr. Shamsheer Vayalil noted that while the initial investments in climate-resilient healthcare may be significant, the long-term benefits are essential for safeguarding global health. He highlighted the Burjeel Holdings Center for Climate and Health—an innovative initiative designed to deliver integrated, climate-resilient solutions by embedding climate-related counseling and preventive strategies directly into clinical care. The center was recently featured in a World Economic Forum whitepaper titled Healthcare in a Changing Climate: Investing in Resilient Solutions , which highlights its introduction of advanced screening for climate-sensitive triggers such as air pollution and extreme heat.
'Burjeel is demonstrating how healthcare providers can play a proactive role in addressing the health impacts of climate change. We've put together a dedicated team who, through our center for climate and health, are transforming care delivery in the face of climate change,' said Dr. Shamsheer Vayalil.
He detailed an innovative program Burjeel will be launching in the summer that will use state-of-the-art Agentic AI to automatically contact at-risk patients—identified by physicians or through its electronic medical record system—to alert them about changes due to extreme weather.
Notable participants in the session included Dr. Orazio Schillaci, Italy's Health Minister, along with Nick Studer of Oliver Wyman, Alan Dangour of the Wellcome Trust, Audrey Duval of Sanofi, Camilla Macapili Languille of Mubadala, Mads Krogsgaard Thomsen of the Novo Nordisk Foundation, Pam Cheng of AstraZeneca, and Peter Sands of The Global Fund. Dr. Victor Dzau of the National Academy of Medicine served as facilitator.
Innovating Cancer Care: Bridging Local Solutions:
At the Annual Meeting 2025, Burjeel Holdings also conducted a WEF-accredited workshop titled 'Innovating Cancer Care: Bridging Local Solutions'. The session brought together multiple stakeholders with a shared interest of optimizing care for cancer patients in emerging markets including key opinion leaders from various sectors: oncology, translational science, AI and digital health, telemedicine and monitoring, decentralized trials, drug development (pharmaceuticals), and healthcare investment. The engaging and interactive workshop for the global experts was led by MSNBC anchor Richard Lui, Profs. Khaled Musallam, Don Dizon, and Garth Powis.
Discussions focused on leveraging emerging technologies to enhance cancer diagnosis, improve treatment accessibility, and reduce costs. Experts examined strategies for addressing affordability and scaling successful local solutions—particularly in emerging markets—to achieve equitable universal cancer treatment .
Speaking on c linical trials and access to innovative medicines, Prof. Khaled Musallam, Group Chief Research Officer, Burjeel Holdings, said, 'One key barrier to importing global clinical trials into emerging markets is lack of inter-country harmonization of regulatory approval pathways, and a considerable time window between clinical trials and marketing authorization – which commonly relies on US or European approvals. Adopting unified standards that meet the evolving requirements of the pharmaceutical industry and ensuring a continuum of access to novel therapies can be a key game changer.'
The experts also discussed encouraging emerging economies that have some available resources to collaborate as best they can in establishing clinics and hospitals where outside funding agencies could provide access to evolving new medical technologies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CairoScene
18-05-2025
- CairoScene
World's First AI Doctor Clinic Opens in Al-Ahsa
Patients at Almoosa Health Group's pilot clinic are now met first by an AI doctor, named 'Dr Hua', with human physicians supervising final diagnoses and treatment plans. Saudi Arabia has launched what is being described as the world's first artificial intelligence-led doctor clinic in the eastern region of Al-Ahsa. The facility, opened by Almoosa Health Group in partnership with Chinese firm Synyi AI, marks a global first in using AI as the primary point of care—while maintaining human medical oversight for safety. At the clinic, patients consult an AI doctor named 'Dr Hua' via tablet interface. The system uses a combination of voice recognition, medical imaging, and interactive questioning to assess symptoms and suggest diagnoses. Human assistants are present throughout the consultation to guide patients and collect supporting data. The AI system currently covers 30 respiratory conditions, such as asthma and pharyngitis, and developers plan to expand its diagnostic range to 50 diseases, including those affecting the digestive and dermatological systems. Treatment plans generated by the AI are reviewed and approved by a licensed physician before any action is taken. According to Synyi AI, pre-trial testing showed an error margin of 0.3%. The system uses large language models that have been adapted to Arabic and local medical terminology to better serve the region's patients. Human doctors remain on-site to verify results and respond to medical emergencies.
Al-Ahram Weekly
14-05-2025
- Al-Ahram Weekly
El-Sisi stresses importance of incorporating AI in education and health
President Abdel-Fattah El-Sisi directed the government on Wednesday to explore the possibility of incorporating Artificial Intelligence (AI) as a mandatory subject in school curricula and to leverage AI applications in healthcare. El-Sisi's directives came during a meeting on Wednesday with Prime Minister Mostafa Madbouly and Deputy Prime Minister for Human Development and Minister of Health and Population Khaled Abdel Ghaffar. According to the Egyptian Presidential Spokesperson Mohamed El-Shennawy, El-Sisi also instructed the government to improve healthcare professionals' working conditions, enhance their participation in modern training programs, and leverage AI applications in healthcare. Health insurance system El-Shennawy noted that Madbouly and Abdel Ghaffar briefed the president on the government's plan for implementing the second phase of the Universal Health Insurance System (UHIS). Phase two will cover the governorates of Damietta, Kafr El-Sheikh, Minya, Matrouh, and North Sinai. It includes developing 11 hospitals and constructing 19 new ones. This brings the total number of hospitals in the designated governorates to 65, with a total capacity of 10,517 beds. The second phase also includes establishing 534 primary healthcare units and centres, including medical and non-medical equipment, at an estimated cost of EGP 115 billion. These additional units and centres bring the total number of healthcare units and centres in the designated governorates to 669. According to the spokesperson, the president, in turn, directed the government to expedite the completion of the second phase. He also stressed the importance of adhering to implementation timelines and meeting the highest quality standards. Digital health system Moreover, El-Shennawy stated that the Minister of Health reviewed steps towards developing a comprehensive digital health system that aligns with Egypt's 2030 Vision. The system aims to improve healthcare quality, facilitate service access, and increase operational efficiency. These steps also include creating electronic health records, applying AI technologies, establishing a national health information exchange platform, and enhancing international partnerships to ensure the sustainability of the digital transformation. In this context, the president directed the government to explore incorporating AI as a mandatory subject in school curricula. Presidential initiatives According to the spokesperson, El-Sisi listened to a presentation about presidential initiatives to improve public health for multiple age groups. These initiatives include examining individuals between birth and five, five and 15, and 18 and 65 through 15 presidential initiatives that provide 234 million health services at 3,527 health units. In addition, El-Shennawy indicated that the president was briefed on the implementation status of the national health projects across the country. These projects include developing and constructing 20 hospitals in 11 governorates, at an estimated cost of EGP 11.7 billion, during the 2025 fiscal year. The 20 hospitals add about 2,649 beds, including 458 ICU beds. They also add 442 incubators, 1,749 inpatient beds, 542 dialysis machines, and 95 operating rooms. Eleven hospitals have been completed in ten governorates. The Ministry of Health has also equipped existing hospitals under its administration with all necessary medical equipment up to the third quarter of the 2024-2025 fiscal year. Furthermore, the spokesperson noted that El-Sisi was updated on the Waiting List Initiative. Since its launch in July 2018, around EGP 24.746 billion has been spent to treat approximately 2.69 million citizens through the initiative. At least 2.1 million citizens were treated at state expense in 2025, and the cost of their treatment is estimated at EGP 23.2 billion. Moreover, El-Shennawy added that the president was briefed on the government's efforts to localise pharmaceutical and medical device manufacturing. In this respect, El-Sisi emphasised providing all the necessary facilities to attract investments in this vital sector, which would meet local market demand and increase Egyptian exports. Human development According to the spokesperson, the president also reviewed the steps the Human Development Ministerial Group has taken to implement the national human development project "Bedaya." These steps include increasing nurseries for children under six and establishing 300 integrated human development centres in different governorates. Similarly, Minister of Health Khaled Abdel Ghaffar presented an overview of the National Population and Development Strategy. The strategy is part of the presidential initiative "Bedaya," which aims to improve demographic characteristics and reduce stunting, obesity, and anaemia rates among children. Abdel Ghaffar also provided an update on the population growth file. He noted that the annual population growth rate decreased by 1.34 percent in 2025, compared to 1.4 percent in 2024. Follow us on: Facebook Instagram Whatsapp Short link:
CairoScene
14-05-2025
- CairoScene
Advanced Cancer Therapy to Be Produced in UAE at 90% Lower Cost
CAR-T cancer therapy—one of the world's most expensive treatments—will soon be produced locally in the UAE at a fraction of the price. Apr 20, 2025 In a major healthcare breakthrough, the UAE is set to manufacture CAR-T cell therapies locally, cutting treatment costs by up to 90% compared to international prices. The initiative, announced during Abu Dhabi Global Health Week, results from a partnership between Burjeel Holdings and US-based non-profit Caring Cross. CAR-T therapy is a next-generation immunotherapy that reprograms a patient's immune cells to target and destroy cancer cells, primarily used to treat aggressive blood cancers like leukemia and lymphoma. With current global treatment prices ranging from USD 350,000 to over USD 1 million, access has remained limited across the MENA region. This new initiative will establish a local manufacturing ecosystem, with Caring Cross supplying the technology, raw materials, and training needed to support point-of-care production. The first phase focuses on leukemia and lymphoma, with plans to expand into treatments for other diseases, including HIV. The partnership aims to position the UAE as a regional hub for advanced cell and gene therapies, enhancing access to life-saving treatments and supporting healthcare sustainability across underserved populations in MENA and beyond.
